MVMaria J. G. T. Vehreschild

Maria J. G. T. Vehreschild

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria J. G. T. Vehreschild has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Oliver Andreas Cornely

    Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine, University of Cologne , Cologne

    6 shared publications
  • J. J. Vehreschild

    1st Department of Internal , University Hospital Cologne , Cologne

    3 shared publications
  • G. Maschmeyer

    Department of Hematology , Oncology and Palliative Care, Ernst-von-Bergmann Klinikum , Potsdam

    2 shared publications
  • Hilmar Wisplinghoff

    Institute for Medical Microbiology, Immunology and Hygiene, University Hospital of Cologne, Germany

    2 shared publications
  • S. Neumann

    Department of Hematology and Oncology , Georg-August-University Göttingen , Göttingen , Germany

    2 shared publications
  • A. M. K. Meissner

    11st Department of Internal Medicine, University of Cologne, Cologne

    1 shared publication

Latest Publications

  • Open Access

    A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies

    by Maria J. G. T. Vehreschild, Axel Hamprecht, Lisa Peterson, Sören Schubert, Maik Häntschel, Silke Peter, Philippe Schafhausen, Holger Rohde, Marie V. Lilienfeld-Toal, Isabelle Bekeredjian-Ding, et al.

    Bloodstream infections (BSIs) caused by enterobacteria remain a leading cause of mortality in patients with chemotherapy-induced neutropenia. The rate and type of colonization and infection with ESBL-producing Enterobacteriaceae (ESBL-E) and their mode of transmission in German cancer centres is largely unknown. We performed a prospective, observational study at five German university-based haematology departments. Participating sites screened for intestinal ESBL-E colonization within 72 h of admission, every 10 ± 2 days thereafter and before discharge. Three of the five centres performed contact isolation for patients colonized or infected with ESBL-E. Molecular characterization of resistance mechanisms and epidemiological typing of isolates by repetitive extragenic palindromic PCR (rep-PCR) and PFGE was performed to assess strain transmission between patients. Between October 2011 and December 2012, 719 hospitalizations of 497 haematological high-risk patients comprising 20 143 patient-days were analysed. Mean duration of in-hospital stay was 36.6 days (range: 2–159 days). ESBL-E were identified from screening samples (82.8% Escherichia coli and 14.6% Klebsiella pneumoniae) in 55/497 patients (11.1%; range by centre: 5.8%–23.1%). PFGE and rep-PCR revealed only a single case of potential cross-transmission among two patients colonized with K. pneumoniae. Six episodes of BSI with ESBL-E were observed. Multivariate analysis revealed previous colonization with ESBL-E as the most important risk factor for BSI with ESBL-E (OR 52.00; 95% CI 5.71–473.89). Even though BSI with ESBL-E is still rare in this high-risk population, colonization rates are substantial and vary considerably between centres. In-hospital transmission of ESBL-E as assessed by molecular typing was the exception.


  • Open Access

    Clostridium Difficile Infection in Patients with Acute Myelogenous Leukemia and in Patients Undergoing Allogeneic Stem Cell Transplantation: Epidemiology and Risk Factor Analysis

    by Maria J.G.T. Vehreschild, David Weitershagen, Lena M. Biehl, Daniela Tacke, Dirk Waldschmidt, Ulrich Töx, Hilmar Wisplinghoff, Michael V. Bergwelt-Baildon, Oliver A. Cornely, Joerg J. Vehreschild


  • Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: A 6‐yr analysis from the cologne cohort for neutropenic patients

    by Maria J. G. T. Vehreschild, Michael von Bergwelt‐Baildon, Liliane Tran, Alexander Shimabukuro‐Vornhagen, Hilmar Wisplinghoff, Christopher Bangard, Oliver Andreas Cornely, Jörg Janne Vehreschild

    Introduction: Invasive fungal diseases (IFDs) are an important cause of morbidity and mortality in patients undergoing allogeneic stem cell transplantation (SCT).Methods: To compare the effectiveness of two prophylactic antifungal regimens used as standard of care (SOC) in the setting of SCT during the periods of May 2006 – September 2009 (oral posaconazole, POS) and October 2009 – July 2011 (oral posaconazole with intravenous micafungin bridging, POS‐MIC), data from the Cologne Cohort of Neutropenic Patients (CoCoNut) study were analyzed after nearest‐neighbor matching. Endpoints were occurrence of breakthrough probable/proven IFD under prophylaxis, incidence and duration of persistent febrile neutropenia, incidence of unspecific pneumonic infiltrates, possible IFD, positive galactomannan tests, as well as fungal‐free and overall survival.Results: Of 291 patients with 307 SCTs observed during the study period, 212 fulfilled the inclusion criteria and were included into the analysis. Patients receiving POS‐MIC were less likely to develop a pneumonic infiltrate (RR 0.71, 95% CI 0.51–1.00) or possible IFD (RR 0.36, 95% 0.15–0.87). They also demonstrated improved fungal‐free survival at day 100 (P = 0.009). No significant differences were observed for the incidence of probable or proven IFD, positive galactomannan tests, persistent febrile neutropenia, duration of hospitalization and overall mortality. There was no grade III or IV CTCAE (Common Terminology Criteria for Adverse Events) toxicity related to antifungal prophylaxis.Conclusion: Our results suggest that both prophylactic regimens, POS and POS‐MIC are feasible, safe and effective. Our data suggest that bridging with intravenous micafungin could indeed improve exposure to antifungal prophylaxis, which may explain the reduced incidence of pneumonia and IFD in the bridging group.


  • Open Access

    Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

    by M. J. G. T. Vehreschild, J. J. Vehreschild, K. Hübel, M. Hentrich, M. Schmidt-Hieber, M. Christopeit, G. Maschmeyer, E. Schalk, O.A. Cornely, S. Neumann

    Cancer patients frequently suffer from gastrointestinal complications. However, a comprehensive, practical and evidence-based guideline on this issue is not yet available. An expert group was put together by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) to develop a guideline on gastrointestinal complications in cancer patients. For each subtopic, a literature search was carried out in PubMed, Medline and Cochrane databases and the strength of recommendation and the quality of the published evidence for major therapeutic strategies were categorized using a modification of the ‘Infectious Diseases Society of America’ criteria. Consensus discussions were held on each of the topics. Recommendations were made with respect to non-infectious and infectious gastrointestinal complications. For all recommendations, the strength of the recommendation and the level of evidence are presented. This guideline is an evidence-based approach to the diagnosis and management of gastrointestinal complications in cancer patients.


  • Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies

    by B. J. Liss, J. J. Vehreschild, O. A. Cornely, M. Hallek, G. Fätkenheuer, H. Wisplinghoff, H. Seifert, M. J. G. T. Vehreschild

    In patients with haematological or oncological malignancies, we aimed to assess the rate of intestinal colonisation and blood stream infections (BSI) with extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) and vancomycin-resistant enterococci (VRE), mortality and risk factors associated with ESBLE/VRE BSI, as well as the impact of faecal screening for ESBLE and VRE in combination with adapted empiric treatment of febrile neutropenia.


  • Open Access

    Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients

    by M. J. G. T. Vehreschild, A. M. K. Meissner, O. A. Cornely, G. Maschmeyer, S. Neumann, M. von Lilienfeld-Toal, M. Karthaus, M. Wattad, P. Staib, M. Hellmich, et al.

    Background Neutropenic patients are at risk of abdominal complications and yet the incidence and impact of these complications on patients’ morbidity and mortality have not been sufficiently evaluated. We aimed to assess a clinical rule for early detection of abdominal complications leading to death or transfer to intensive care in patients with chemotherapy-associated neutropenia. Design and Methods This observational multicenter study was carried out in seven German hematology-oncology departments. For inclusion, neutropenia of at least 5 consecutive days was required. Risk factors for “transfer to intensive care” and “death” were assessed by backward-stepwise binary logistic regression analyses. Chemotherapy-associated bowel syndrome was defined as a combination of fever (T ≥37.8 °C) and abdominal pain and/or lack of bowel movement for 72 hours or more. Five hundred and twenty-one neutropenic episodes were documented in 359 patients. Results The incidence of chemotherapy-associated bowel syndrome was 126/359 (35%) in first episodes of neutropenia. Transfer to intensive care occurred in 41/359 (11%) and death occurred in 17/359 (5%) first episodes. Chemotherapy-associated bowel syndrome and duration of neutropenia were identified as risk factors for transfer to intensive care (PP=0.003; OR 1.061/d; 95% CI 1.021–1.103). Chemotherapy-associated bowel syndrome and mitoxantrone administration were identified as risk factors for death (P=0.005; OR 4.611; 95% CI 1.573–13.515 and P=0.026; OR 3.628; 95% CI 1.169–11.256). Conclusions The occurrence of chemotherapy-associated bowel syndrome has a significant impact on patients’ outcome. In future interventional clinical trials, this definition might be used as a selection criterion for early treatment of patients at risk of severe complications.